Coleman, Robert E.
Croucher, Peter I.
Padhani, Anwar R.
Clézardin, Philippe
Chow, Edward
Fallon, Marie
Guise, Theresa
Colangeli, Simone
Capanna, Rodolfo
Costa, Luis
Article History
Accepted: 1 September 2020
First Online: 15 October 2020
Competing interests
: R.E.C. has received honoraria from Amgen and Novartis, and has stock options with Inbiomotion related to a patented biomarker. P.I.C. is the recipient of a grant from Amgen, and received honoraria and participated in advisory boards from Amgen. P.C. has received honoraria from Amgen. L.C. has received research grants from Amgen, Bayer, Novartis and Roche, speaker honoraria from Amgen, Bayer, Janssen, Lilly and Roche, and is also a consultant for Amgen, Novartis and Servier. All other authors declare no competing interests.